Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Advanced Breast Carcinoma 1

Interventions

pembrolizumab 603Cyclophosphamide 545Magnetic Resonance Spectroscopy 527Radiotherapy 513Specimen Handling 505Nivolumab 411Cisplatin 381Carboplatin 369Biopsy 305Blood Specimen Collection 304Radiosurgery 290Paclitaxel 281Gemcitabine 271Surveys and Questionnaires 269Standard of Care 267fludarabine 263Drug Therapy 263Dexamethasone 263Bevacizumab 252venetoclax 251Oxaliplatin 209Capecitabine 199Rituximab 198Radiation 191Ipilimumab 188Fluorouracil 188durvalumab 185Doxorubicin 178Etoposide 177atezolizumab 172

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × TVB-2640 × 1 year × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

NCT05743621 2025-11-21

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

Weill Medical College of Cornell University

Phase 1 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡